Srikala Sridhar, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, describes a retrospective chart review presented at ASCO GU 2021 of patients with metastatic urothelial carcinoma (mUC) treated with front-line platinum-based chemotherapy from 2005-2018, with the aim of assessing the prognostic impact of bone metastasis on survival outcomes. This study suggested that bone metastasis is a significant predictor of worse outcomes in front-line platinum-based chemotherapy-treated mUC and suggests further study in to bone-targeted agents is necessary. This interview took place during the 2021 Genitourinary Cancers Symposium.
